In a welcome move, Viridian Therapeutics saw its Relative Strength Rating improve from 62 to 79 on Thursday.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history reveals that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 in the early stages of their moves. See if Viridian Therapeutics can continue to rebound and hit that benchmark.
While now is not an ideal time to jump in, see if the stock goes on to establish and enter a buying range in heavy trade.
Viridian Therapeutics reported 0% EPS growth last quarter. Sales gains came in at 0%. The next quarterly results are expected on or around Aug. 6.
The company earns the No. 274 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
